Tubulis
Latest round
- Series C
Last raised
- Oct 2025
Total raised
- $613M
Investors
- 21
About Tubulis
Founded in 2016, Based in Germany, Tubulis GmbH is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for targeted cancer therapies, aiming to improve treatment efficacy while reducing harm to healthy cells.586 mn post-money. Tubulis specializes in the development of innovative antibody-drug conjugates (ADCs), focusing on targeted cancer therapies. Their core product, TUB-030, is currently in a Phase I/IIa trial for advanced solid tumors. The technology uses antibodies to deliver cytotoxic agents directly to cancer cells, enhancing therapeutic efficacy while minimizing damage to healthy tissues. Tubulis' ADCs target oncologists and healthcare institutions in North America and Europe, and their strategic collaborations, such as a recent licensing agreement with BMS, expand their presence in the pharmaceutical landscape, addressing the needs of cancer patients and healthcare providers. Tubulis generates revenue through strategic partnerships and licensing agreements with established pharmaceutical companies. Their financial model includes upfront payments, milestone payments linked to developmental targets, and royalties from future sales of therapies.
Who invested in Tubulis
21 investors across 5 rounds
See all investors in Tubulis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Tubulis
Who invested in Tubulis?
Tubulis has 21 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tubulis raised?
Tubulis has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Tubulis last raise money?
Tubulis's most recent round on record is a Series C, in Oct 2025.
What does Tubulis do?
Founded in 2016, Based in Germany, Tubulis GmbH is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for targeted cancer therapies, aiming to improve treatment efficacy while reducing harm to healthy cells.
Where is Tubulis headquartered?
Tubulis is headquartered in Munich, Germany.
Which VCs invest in companies like Tubulis?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Tubulis's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Tubulis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.